Diana De Graeve
Diana De Graeve
professor of economics University of Antwerpen
Geverifieerd e-mailadres voor uantwerpen.be - Homepage
Geciteerd door
Geciteerd door
Equity in the delivery of health care in Europe and the US
E Van Doorslaer, A Wagstaff, H Van der Burg, T Christiansen, ...
Journal of health economics 19 (5), 553-583, 2000
A typology for provider payment systems in health care
M Jegers, K Kesteloot, D De Graeve, W Gilles
Health policy 60 (3), 255-273, 2002
Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries
A Ament, R Baltussen, G Duru, C Rigaud-Bully, D De Graeve, ┼ Írtqvist, ...
Clinical Infectious Diseases 31 (2), 444-450, 2000
Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis
D De Graeve, A Smet, A Mehnert, S Caleo, H Miadi-Fargier, ...
Pharmacoeconomics 23 (1), 35-47, 2005
The distributional impact of health financing in Europe: A review
D De Graeve, T Van Ourti
World Economy 26 (10), 1459-1479, 2003
Supplemental health insurance and equality of access in Belgium
E Schokkaert, T Van Ourti, D De Graeve, A Lecluyse, C Van de Voorde
Health economics 19 (4), 377-395, 2010
Healthcare use, social burden and costs of children with and without ADHD in Flanders, Belgium
A De Ridder, D De Graeve
Clinical drug investigation 26 (2), 75-90, 2006
Economic aspects of pneumococcal pneumonia
D De Graeve, P Beutels
Pharmacoeconomics 22 (11), 719-740, 2004
Introduction to special issue on the economics of health insurance in low and middle-income countries
G Carrin, D De Graeve, L DevillÚ
Social science & medicine (1982) 48 (7), 859-864, 1999
Direct costs of health care for HIV/AIDS patients in Belgium
RC Decock, AME Depoorter, DD Graeve, R Colebunders
AIDS care 13 (6), 721-731, 2001
Cost-effectiveness analysis of pneumococcal vaccination of adults and elderly persons in Belgium
D De Graeve, G Lombaert, H Goossens
Pharmacoeconomics 17 (6), 591-601, 2000
Experience: the most critical factor in choosing after-hours medical care
H Philips, D Mahr, R Remmen, M Weverbergh, D De Graeve, ...
Quality and Safety in Health Care 19 (6), e3-e3, 2010
Drug eluting stents in Belgium: health technology assessment
M Neyt, H Van Brabandt, S Devriese, J Mahieu, A De Ridder, ...
Brussel: Federaal Kenniscentrum voor de Gezondheidszorg, 2007
Comparing the cost effectiveness of risperidone and olanzapine in the treatment of schizophrenia using the net-benefit regression approach
A De Ridder, D De Graeve
Pharmacoeconomics 27 (1), 69-80, 2009
Recommended structure for reporting economic evaluation on pharmaceuticals in Belgium
L Annemans, R Crott, D Degraeve, D Dubois, M Huybrechts, F Peys, ...
Pharmacy World and Science 24 (1), 5-7, 2002
Evaluatie van de effecten van de maximumfactuur op de consumptie en financiŰle toegankelijkheid van de gezondheidszorg
E Schokkaert, J Guillaume, A Lecluyse, H Avalosse, K Cornelis, ...
KCE Reports 80, 2008
Disease burden and medical cost-analysis of Acute Respiratory Infections in a low-income district of Bogotß
CA Lara-Oliveros, D De Graeve, F Franco, SP Daza
Revista de Salud P˙blica 18, 568-580, 2016
Pharmacoeconomics of Immunisation
R Van den Oever, D De Graeve, B Hepp, A Stroobant, D Walckiers, ...
PharmacoEconomics 3 (4), 286-308, 1993
Predicting the place of out-of-hours care—a market simulation based on discrete choice analysis
H Philips, D Mahr, R Remmen, M Weverbergh, D De Graeve, ...
Health Policy 106 (3), 284-290, 2012
Belgian Schizophrenia Outcome Survey–Results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol
J Peuskens, B Gillain, D De Graeve, B Van Vleymen, A Albert
European psychiatry 24 (3), 154-163, 2009
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20